贝伐单抗治疗晚期结直肠癌疗效预后相关标志的研究进展  

The research progress and prospect about the predictive or prognostic factors for bevacizumab therapy in metastatic colorectal cancer :a systematic review

作　　者：任安晶 朱陵君[1] 杜海娜 陈志鹏[3] 

机构地区：[1]南京医科大学第一附属医院肿瘤科,江苏南京210029 [2]南京中医药大学第三附属医院肿瘤科,江苏南京210029 [3]张家港市第一人民医院肿瘤科,江苏苏州215600

出　　处：《南京医科大学学报（自然科学版）》2016年第3期274-279,共6页Journal of Nanjing Medical University(Natural Sciences)

基　　金：国家自然科学基金(81472634)

摘　　要：贝伐单抗作为首个FDA批准上市的抗肿瘤血管靶向药物,目前临床上已广泛应用于晚期结直肠癌的一线治疗。但其疗效及预后相关的明确预测因子尚无定论。为了解决这一临床难题,筛选贝伐单抗的优势人群,实现精准治疗,学者们在此领域进行了多方探索,本文就近年来该方向的研究进展进行综述。Bevacizumab（BEV）,as the first antiangiogenic targeted drug approved by FDA in 2004,has been applied to first-line treatment of metastatic colorectal cancer（m CRC） wildly at present. However,no predictive marker has been identified yet for the efficacy and prognosis of BEV. To solve the clinical problem and determine the individuals who will acquire more benefits from BEV and achieve precise treatment,scholars have carried out many explorations in this field. A literature review was conducted to summarize the research progress and prospect about the predictive factors of BEV in the past years.

关 键 词：贝伐单抗 晚期结直肠癌 精准治疗 

分 类 号：R735.3[医药卫生—肿瘤]